Blood-brain barrier and Alzheimer's disease

Brain and Nerve

Volumn 65, Issue 2, 2013, Pages 145-151

  Kuwahara, Hiroya ^a,b   Nishida, Yoichiro ^a,c   Yokota, Takanori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN BOKUTOH HOSPITAL   (Japan)

^c Saitama Prefectural Rehabilitation Center   (Japan)

Author keywords

Alzheimer's disease; Amyloid cascade hypothesis; Blood brain barrier; Peripheral sink; Vascular hypothesis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; LOW DENSITY LIPOPROTEIN RECEPTOR; MULTIDRUG RESISTANCE PROTEIN;

ALZHEIMER DISEASE; BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN PERFUSION; DEMENTIA; DIABETES MELLITUS; DISEASE ACTIVITY; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHESIS; MEMBRANE TRANSPORT; OBESITY; PROTEIN MODIFICATION; PROTEIN TRANSPORT; REGULATORY MECHANISM; REVIEW; RISK FACTOR; VASCULAR DISEASE;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; ANTIBODIES; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; HUMANS;

EID: 84874617258     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Querfurth HW, LaFerla FM: Alzheimer's disease. N Engl J Med 362: 329-344, 2010
2. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ: Structure and function of the blood-brain barrier. Neurobiol Dis 37: 13-25, 2010
3. Yan SD, Chen X, Fu J, Chen M, Zhu H, et al: RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691, 1996 (Pubitemid 26282167)
4. Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, et al: RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 9: 907-913, 2003 (Pubitemid 36889934)
5. Giri R, Shen Y, Stins M, Du Yan S, Schmidt AM, et al: Beta-amyloid-induced migration of monocytes across human brain endothelial cells involves RAGE and PECAM-1. Am J Physiol Cell Physiol 279: C1772-C1781, 2000
6. Shayo M, McLay RN, Kastin AJ, Banks WA: The putative blood-brain barrier transporter for the beta-amyloid binding protein apolipoprotein j is saturated at physiological concentrations. Life Sci 60: PL 115-118, 1997
7. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, et al: Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330: 1774, 2010
8. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, et al: LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43: 333-344, 2004 (Pubitemid 39061126)
9. Kang DE, Saitoh T, Chen X, Xia Y, Masliah E, et al: Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology 49: 56-61, 1997 (Pubitemid 27328682)
10. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, et al: Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci Transl Med 3: 89ra57, 2011
11. Owen JB, Sultana R, Aluise CD, Erickson MA, Price TO, et al: Oxidative modification to LDL receptor-related protein 1 in hippocampus from subjects with Alzheimer disease: implications for Aβ accumulation in AD brain. Free Radic Biol Med 49: 1798-1803, 2010
12. Behl M, Zhang Y, Shi Y, Cheng J, Du Y, et al: Lead-induced accumulation of beta-amyloid in the choroid plexus: role of low density lipoprotein receptor protein-1 and protein kinase C. Neurotoxicology 31: 524-532, 2010
13. Tamaki C, Ohtsuki S, Iwatsubo T, Hashimoto T, Yamada K, et al: Major involvement of low-density lipoprotein receptor-related protein 1 in the clearance of plasma free amyloid beta-peptide by the liver. Pharm Res 23: 1407-1416, 2006 (Pubitemid 43993806)
14. Sagare A, Deane R, Bell RD, Johnson B, Hamm K, et al: Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 13: 1029-1031, 2007 (Pubitemid 47517512)
15. Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, et al: Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab 27: 909-918, 2007 (Pubitemid 46659038)
16. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, et al: P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115: 3285-3290, 2005 (Pubitemid 41567593)
17. van Assema DM, Lubberink M, Bauer M, van der Flier WM, Schuit RC, et al: Blood-brain barrier P-glycoprotein function in Alzheimer's disease. Brain 135: 181-189, 2012
18. Jellinger KA: Prevalence and impact of cerebrovascular lesions in Alzheimer and lewy body diseases. Neurodegener Dis 7: 112-115, 2010
19. Marchesi VT: Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: implications for early detection and therapy. FASEB J 25: 5-13, 2011
20. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, et al: Brain infarction and the clinical expression of Alzheimer disease: The Nun Study. JAMA 277: 813-817, 1997 (Pubitemid 27111317)
21. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, et al: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 348: 1215-1222, 2003 (Pubitemid 36359297)
22. Ruitenberg A, den Heijer T, Bakker SL, van Swieten JC, Koudstaal PJ, et al: Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study. Ann Neurol 57: 789-794, 2005 (Pubitemid 40798616)
23. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, et al: Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53: 1937-1942, 1999
24. Nagai M, Hoshide S, Kario K: Hypertension and dementia. Am J Hypertens 23: 116-124, 2010
25. Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, et al: Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137: 149-155, 2002 (Pubitemid 34827510)
26. Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kåreholt I, et al: Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease. Arch Neurol 62: 1556-1560, 2005 (Pubitemid 41434560)
27. Zlokovic BV: Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 12: 723-738, 2011
28. Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, et al: Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485: 512-516, 2012
29. Bennett SA, Pappas BA, Stevens WD, Davidson CM, Fortin T, et al: Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol Aging 21: 207-214, 2000 (Pubitemid 30387079)
30. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al: Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177, 1999 (Pubitemid 29327547)
31. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, et al: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med 9: 448-452, 2003 (Pubitemid 36460079)
32. Citron M: Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov 9: 387-398, 2010
33. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, et al: Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98: 8850-8855, 2001 (Pubitemid 32678116)
34. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, et al: Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 8: 261-271, 2012
35. Matsuoka Y, Saito M, LaFrancois J, Saito M, Gaynor K, et al: Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 23: 29-33, 2003 (Pubitemid 36050401)
36. Deane R, Singh I, Sagare AP, Bell RD, Ross NT, et al: A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease. J Clin Invest 122: 1377-1392, 2012
37. Sabbagh MN, Agro A, Bell J, Aisen PS, Schweizer E, et al: PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease. Alzheimer Dis Assoc Disord 25: 206-212, 2011
38. Qosa H, Abuznait AH, Hill RA, Kaddoumi A: Enhanced brain amyloid-β clearance by rifampicin and caffeine as a possible protective mechanism against Alzheimer's disease. J Alzheimers Dis 31: 151-165, 2012
39. Castellano JM, Deane R, Gottesdiener AJ, Verghese PB, Stewart FR, et al: Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc Natl Acad Sci U S A 109: 15502-15507, 2012
40. Hoffman LB, Schmeidler J, Lesser GT, Beeri MS, Purohit DP, et al: Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons. Neurology 72: 1720-1726, 2009